NCT01981616View on ClinicalTrials.gov

Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab

PHASE1CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

July 31, 2012

Conditions
Inflammatory Bowel Disease
Interventions
DRUG

Vedolizumab

Vedolizumab for intravenous infusion

DRUG

Placebo

Placebo intravenous infusion

BIOLOGICAL

Hepatitis B vaccine

BIOLOGICAL

Oral cholera vaccine

Trial Locations (1)

Unknown

ICON Development Solutions, Manchester

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01981616 - Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab | Biotech Hunter | Biotech Hunter